Corporate & Financial Highlights - Chimeric raised $16.6 million, including $5.6 million from a US Family Office[7] - The company fully paid out the Lind facility by the end of July 2025[7] - Significant headcount and cost reductions were implemented[7] - The company's market capitalization is approximately $10 million[23] - There are approximately 1.6 billion shares on issue[23] CHM CDH17 CAR-T Trial - The trial has commenced, with 5 patients treated[7] - Dose level 1 (50m Cells) is completed, showing stable disease at 6 months[7] - In Dose Level 1, Patient 2 and Patient 3 with NET and CRC respectively, showed stable disease until day 150[12] - Dose level 2 (150m Cells) has commenced[7] - 8/8 GMP manufacturing runs were successful[7] CHM CORE-NK Trial - Dose finding has been completed for 'OFF THE SHELF' NK[7] - The Frontline ADVENT AML trial has commenced[7] - 2 patients achieved CRi (Complete response with incomplete blood count recovery)[7] - In the Frontline Phase 1 study, 2 out of 3 patients with AML achieved a complete response[17]